Company Overview

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. The United States segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides central specialty pharmacy services and mail services. As of August 31, 2021, this segment operated 8,965 retail stores under the Walgreens and Duane Reade brands in the United States; and five specialty pharmacies. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. As of August 31, 2021, this segment operated 4,031 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 548 optical practices, including 160 on a franchise basis. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.

  • Name

    Walgreens Boots Alliance, Inc.

  • CEO

    Mr. Timothy C. Wentworth

  • Website

    www.walgreensbootsalliance.com

  • Sector

    Consumer Staples Distribution and Retail

  • Year Founded

    1909

Profile

  • Market Cap

    $7,570.92M

  • EV

    $42.31B

  • Shares Out

    863.28M

  • Revenue

    $145.53B

  • Employees

    268,500

Margins

  • Gross

    18.38%

  • EBITDA

    2.72%

  • Operating

    1.29%

  • Pre-Tax

    -9.32%

  • Net

    -3.99%

  • FCF

    -0.61%

Returns (5Yr Avg)

  • ROA

    0.99%

  • ROTA

    3.55%

  • ROE

    2.81%

  • ROCE

    5.4%

  • ROIC

    3.45%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $12.81

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $711M

  • Net Debt

    $32.95B

  • Debt/Equity

    2.18

  • EBIT/Interest

    3.54

Growth (CAGR)

  • Rev 3Yr

    4.2%

  • Rev 5Yr

    1.31%

  • Rev 10Yr

    6.81%

  • Dil EPS 3Yr

    36.65%

  • Dil EPS 5Yr

    5.69%

  • Dil EPS 10Yr

    8.76%

  • Rev Fwd 2Yr

    2.98%

  • EBITDA Fwd 2Yr

    -11.11%

  • EPS Fwd 2Yr

    -28.11%

  • EPS LT Growth Est

    -24.69%

Dividends

  • Yield

  • Payout

    -21.68%

  • DPS

    $1.46

  • DPS Growth 3Yr

    -7.92%

  • DPS Growth 5Yr

    -3.67%

  • DPS Growth 10Yr

    1.48%

  • DPS Growth Fwd 2Yr

    1.51%

NasdaqGS:WBA